Article Text

Download PDFPDF

821 The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1
  1. Shuang Dai1,
  2. Weifeng Huang1,
  3. Longjun Yan1,
  4. Shaogang Peng1,
  5. Shihui Zhou1,
  6. Zhijun Yuan2,
  7. Chao Wang2,
  8. Chuan-Chu Chou2,
  9. Andy Tsun2 and
  10. Tianhang Zhai1
  1. 1Biotheus (Suzhou) Co., Ltd., Suzhou, China
  2. 2Biotheus Inc., Zhuhai, China


Background FOXP3+ Regulatory T cells (Tregs) play a critical role in mediating tolerance to self-antigens but can repress anti-tumor immunity through multiple mechanisms. TGF-β is a potent immunosuppressive cytokine that acts as an essential factor during the differentiation of Treg cells. Therefore, targeted depletion of tumor-promoting Tregs is warranted to promote effective anti-tumor immunity while preserving peripheral homeostasis. CCR8 is a chemokine receptor that has recently been identified as a specific marker for tumor-infiltrating Tregs. Preclinical mouse tumor models have shown that the depletion of CCR8+ Tregs by anti-CCR8 monoclonal antibodies (mAbs) and FcγR engagement, but not ligand blockade, enables effective and long-lasting anti-tumor immunity in combination with PD-1 blockade. Several ADCC function-enhanced anti-CCR8 mAbs have been approved for clinical study both as a monotherapy and combined with PD-1 blockade. However, whether ADCP function enhancement would further potentiate anti-CCR8-mediated Treg depletion is still unknown. Here, we reveal an Fc-optimized anti-CCR8 mAb, which shows stronger ADCC and ADCP function than a wildtype IgG1 control. To explore potential combination strategies in the clinic, we also investigated the synergistic potential of combining the anti-CCR8 mAb with an anti-PD-L1 mAb fused to the extracellular domain of the human TGF-β receptor II (TGFβRII) via a flexible linker, to neutralize TGF-β (anti-PD-L1-β trap).

Methods Effector function-optimized anti-CCR8 mAbs were generated by the mutation of Fc residues plus expression in a fut8-/- CHO cell line. ADCC and ADCP function was detected in both luciferase reporter cell line and primary cells. In vivo efficacy studies using anti-muCCR8-mG2a combined with an anti-PD-L1-β trap was conducted in a CT-26 colon carcinoma model.

Results Fc-optimized anti-CCR8 mAb showed stronger ADCC and ADCP function than the version containing wildtype IgG1 Fc in in vitro assays. The combination of anti-CCR8 mAb and anti-PD-L1-β trap more effectively controlled in vivo tumor growth compared to both monotherapies. We hypothesize that this potent anti-tumor immune response is propagated by the synergy of activating tumor infiltrating lymphocytes and the depletion of tumor-infiltrating Treg cells.

Conclusions We successfully generated an Fc-optimized anti-CCR8 mAb with both ADCC and ADCP enhancement. We also highlight the potential clinical combination benefit of anti-CCR8 mAbs with agents simultaneously blocking the PD1/L1 and TGF-β pathways.

Ethics Approval All mice were maintained under specified pathogen-free conditions, and all studies were approved by the Animal Care and Use Committee of HUST-Suzhou Institute for Brainsmatics.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.